SCHEMBL21296920

SCHEMBL21296920

COc1ccc(Cn2nnc(C(=O)O)c2Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 4/20 0.51
ALOX15 P16050 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
AKR1C3 P42330 3/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 3/20 0.46
POLB P06746 2/20 0.45
MCL1 Q07820 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CYP19A1 P11511 1/20 0.44
CCR2 P41597 1/20 0.44
PDE8B O95263 1/20 0.43
HPGD P15428 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22815761 0.90 CCR2 (0.50) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A
SCHEMBL21296928 0.89 ALOX15 (0.49) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A
SCHEMBL22815786 0.87 ALOX15 (0.56) ALOX15L3MBTL1AKR1C3KMT2AMEN1
SCHEMBL22815906 0.87 ALOX15 (0.47) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A
SCHEMBL22816607 0.87 CCR2 (0.47) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A
SCHEMBL22815736 0.87 MAPT (0.48) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A
SCHEMBL23319956 0.87 NPBWR1 (0.51) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A
SCHEMBL21296893 0.86 CYP19A1 (0.56) NPBWR1ALOX15L3MBTL1KMT2AMEN1
SCHEMBL23484637 0.86 NPBWR1 (0.53) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A
SCHEMBL22816232 0.86 TP53 (0.49) NPBWR1ALOX15L3MBTL1AKR1C3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX NPBWR1 2573/4885ALOX15 127/4885L3MBTL1 2663/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX NPBWR1 2573/4885ALOX15 127/4885L3MBTL1 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.